Ultivue Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 73
Employees
  • Latest Deal Type
  • Series D
  • Latest Deal Amount
  • $50M
Latest Deal Amount
  • Investors
  • 10

Ultivue General Information

Description

Developer of multiplex biomarker assays designed for tissue phenotyping and digital pathology. The company's multiplex immunofluorescence assays offer advanced exploration and interrogation of tissue samples for precision medicine research, enabling researchers and clinicians to strengthen and accelerate biomarker discovery and drug development programs.

Contact Information

Website
www.Ultivue.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 763D Concord Avenue
  • Cambridge, MA 02138-1044
  • United States
+1 (617) 000-0000

Ultivue Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ultivue Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D) 22-Apr-2021 $50M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C1) 22-Sep-2020 0000 000.00 0000 Completed Generating Revenue
3. Later Stage VC (Series C) 01-May-2019 000.00 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series B) 31-Jan-2018 $20.2M $25.4M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 21-Aug-2015 $5.15M $5.15M 000.00 Completed Startup
To view Ultivue’s complete valuation and funding history, request access »

Ultivue Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C-1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 15,100,668 $0.000100 $0.11 $1.34 $1.34 1x $1.34 16.48%
Series A 5,150,000 $0.000100 $1 $1 1x $1 5.62%
To view Ultivue’s complete cap table history, request access »

Ultivue Executive Team (12)

Name Title Board Seat Contact Info
Jacques Corriveau Chief Executive Officer & President
Richard Malabre Chief Financial Officer
Anna Pevzner Senior Director, Financial Planning & Analysis & Controller
Louis Levy Director, Business Development and Corporate
Ralf Jungmann Co-Founder
You’re viewing 5 of 12 executive team members. Get the full list »

Ultivue Board Members (12)

Name Representing Role Since
Adam Wieschhaus Ph.D Self Board Member 000 0000
Andrew Stevenson Ultivue Board Member 000 0000
Daguang Wang Ph.D Self Board Member 000 0000
David Walt Ph.D Self Co-Founder & Board Member 000 0000
Keith Crandell ARCH Venture Partners Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Ultivue Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ultivue Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Ally Bridge Group PE/Buyout Minority 000 0000 000000 0
Pura Vida Investments Hedge Fund Minority 000 0000 000000 0
Tao Capital Partners Venture Capital Minority 000 0000 000000 0
Northpond Ventures Venture Capital Minority 000 0000 000000 0
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »